CN1688715A - 用于确定肾中毒的标记基因 - Google Patents

用于确定肾中毒的标记基因 Download PDF

Info

Publication number
CN1688715A
CN1688715A CNA038187833A CN03818783A CN1688715A CN 1688715 A CN1688715 A CN 1688715A CN A038187833 A CNA038187833 A CN A038187833A CN 03818783 A CN03818783 A CN 03818783A CN 1688715 A CN1688715 A CN 1688715A
Authority
CN
China
Prior art keywords
nephrotoxicity
aldolase
clusterin
egf
numerical value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038187833A
Other languages
English (en)
Chinese (zh)
Inventor
S-D·希布
O·格勒内
G·英伯特
J·克伦
F·施泰特勒
C·D·沃尔夫冈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1688715A publication Critical patent/CN1688715A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA038187833A 2002-07-04 2003-07-03 用于确定肾中毒的标记基因 Pending CN1688715A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0215509.1 2002-07-04
GBGB0215509.1A GB0215509D0 (en) 2002-07-04 2002-07-04 Marker genes

Publications (1)

Publication Number Publication Date
CN1688715A true CN1688715A (zh) 2005-10-26

Family

ID=9939850

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038187833A Pending CN1688715A (zh) 2002-07-04 2003-07-03 用于确定肾中毒的标记基因

Country Status (10)

Country Link
US (1) US20060008804A1 (enExample)
EP (2) EP1925677A3 (enExample)
JP (2) JP2005531321A (enExample)
CN (1) CN1688715A (enExample)
AU (1) AU2003250879B2 (enExample)
BR (1) BR0312405A (enExample)
CA (1) CA2493860A1 (enExample)
GB (1) GB0215509D0 (enExample)
IL (1) IL165883A0 (enExample)
WO (1) WO2004005544A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264230A (zh) * 2008-11-10 2011-11-30 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
WO2013038369A1 (en) * 2011-09-14 2013-03-21 Basf Se Means and methods for assessing kidney toxicity

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500879A (ja) 2000-06-16 2004-01-15 バイオジェン　インコーポレイテッド 腎の調節エレメントおよびそれらの使用方法
DK1401869T3 (da) 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
CA2512138C (en) 2002-12-30 2013-07-16 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2565701A1 (en) * 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
DK1831699T3 (da) * 2004-12-20 2010-03-15 Antibodyshop As Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme
EP1865985B1 (en) 2005-03-02 2010-08-25 Biogen Idec MA Inc. Kim-1 antibodies for treatment of th2-mediated conditions
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20070087387A1 (en) 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
PL2035835T3 (pl) * 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
WO2008017306A1 (en) * 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
EP2137538B1 (en) * 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
EP2479571A3 (en) 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
EP2215481B2 (en) * 2007-11-15 2017-01-18 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
EP2075343A1 (en) * 2007-12-21 2009-07-01 Gert Mayer A method of diagnosing a progressive disease
US8338096B2 (en) * 2008-04-15 2012-12-25 Rainer Oberbauer Markers of acute kidney failure
US7977110B2 (en) 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
ES2341419B1 (es) * 2008-08-14 2011-05-03 Hospital Clinic I Provincial De Barcelona Wnt1 como biomarcador de daño renal.
WO2010054025A1 (en) * 2008-11-05 2010-05-14 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use
EP2364370B1 (en) * 2008-11-22 2014-09-03 Astute Medical, Inc. Methods for prognosis of acute renal failure
EP2379752B1 (fr) * 2009-01-19 2015-09-30 Biomérieux S.A. Procedes pour determiner la susceptibilite a contracter une infection nosocomiale chez un patient et pour etablir un pronostic d'evolution d'un syndrome septique
DK2391653T3 (en) * 2009-01-28 2015-02-09 Ind Tech Res Inst Biomarkers associated nephropathy
WO2011017685A1 (en) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Methods and devices for detecting kidney transplant rejection
ES2530866T3 (es) 2009-12-21 2015-03-06 Mayo Foundation Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF
US9476868B2 (en) 2009-12-23 2016-10-25 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
JP5804629B2 (ja) * 2011-07-29 2015-11-04 株式会社メディクローム 遺伝子発現変動解析による化学物質の毒性評価方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013334276B2 (en) 2012-10-24 2019-07-04 ProKidney IPCo, LLC Renal cell populations and uses thereof
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10420337B2 (en) 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
WO2014182330A1 (en) 2013-05-06 2014-11-13 Hitachi Chemical Company Ltd Devices and methods for capturing target molecules
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015153860A1 (en) * 2014-04-04 2015-10-08 Somalogic, Inc. Glomerular filtration rate biomarkers and uses thereof
WO2015160805A1 (en) * 2014-04-15 2015-10-22 The Brigham And Women's Hospital, Inc. Circulating kim-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
US10801066B2 (en) 2014-09-05 2020-10-13 American University Of Beirut Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger RNA
WO2016077537A1 (en) * 2014-11-12 2016-05-19 Hitachi Chemical Co., Ltd. Method and device for diagnosing organ injury
WO2016208776A1 (ja) 2015-06-25 2016-12-29 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
JP6624704B2 (ja) 2015-08-31 2019-12-25 日立化成株式会社 尿路上皮疾患の評価のための分子法
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
JP6332780B2 (ja) 2016-03-29 2018-05-30 株式会社国際電気通信基礎技術研究所 医薬組成物又は食品組成物、及び有効成分の体内での効果の評価方法
EP3472347B1 (en) * 2016-06-17 2023-01-04 F. Hoffmann-La Roche AG In vitro nephrotoxicity screening assay
US12174201B2 (en) 2017-10-12 2024-12-24 Cedars-Sinai Medical Center Prognosis and progression biomarkers for chronic kidney disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA951461B (en) * 1994-02-22 1996-01-24 Univ Illinois Genes and genetic elements associated with sensitivity to platimun-based drugs
US6586389B1 (en) * 1998-01-22 2003-07-01 Administrators Of The Tulane Educational Fund Cubilin protein, DNA sequences encoding cubilin and uses thereof
CA2340589A1 (en) * 1998-08-28 2000-03-09 Incyte Pharmaceuticals, Inc. Toxicological response markers
WO2000047761A2 (en) * 1999-02-12 2000-08-17 Phase-1 Molecular Toxicology, Inc. High-throughput toxicological testing using cultured organisms and cells
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
AU1466001A (en) * 1999-11-05 2001-05-14 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
US20020037508A1 (en) * 2000-01-19 2002-03-28 Michele Cargill Human single nucleotide polymorphisms
AU2001275346A1 (en) * 2000-06-05 2001-12-17 General Hospital Corporation Compositions, kits, and methods for identification and modulation of type i diabetes
JP2004500879A (ja) * 2000-06-16 2004-01-15 バイオジェン　インコーポレイテッド 腎の調節エレメントおよびそれらの使用方法
EP1356093A2 (en) * 2000-06-21 2003-10-29 Hitachi Chemical Co., Ltd. Gene markers for lung cancer
AU2001271998A1 (en) * 2000-07-13 2002-01-30 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease
AU2001281322A1 (en) * 2000-07-13 2002-01-30 Biogen, Inc. Methods of identifying renal protective factors
JP2004522411A (ja) * 2000-07-31 2004-07-29 ジーン ロジック インコーポレイテッド 分子毒性学モデリング
DE10056802B4 (de) * 2000-11-14 2005-06-16 Epigenomics Ag Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik
CA2440008A1 (en) * 2001-01-29 2002-08-29 Phase-1 Molecular Toxicology, Inc. Rat toxicologically relevant genes and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264230A (zh) * 2008-11-10 2011-11-30 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN102264230B (zh) * 2008-11-10 2014-12-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
WO2013038369A1 (en) * 2011-09-14 2013-03-21 Basf Se Means and methods for assessing kidney toxicity
CN103814295A (zh) * 2011-09-14 2014-05-21 巴斯夫欧洲公司 用于评估肾毒性的手段和方法

Also Published As

Publication number Publication date
WO2004005544A3 (en) 2004-04-22
AU2003250879B2 (en) 2007-07-26
EP1925677A2 (en) 2008-05-28
IL165883A0 (en) 2006-01-15
CA2493860A1 (en) 2004-01-15
JP2005531321A (ja) 2005-10-20
EP1521847A2 (en) 2005-04-13
WO2004005544A2 (en) 2004-01-15
AU2003250879A1 (en) 2004-01-23
US20060008804A1 (en) 2006-01-12
EP1925677A3 (en) 2008-07-02
BR0312405A (pt) 2005-04-26
GB0215509D0 (en) 2002-08-14
JP2010042019A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
AU2003250879B2 (en) Marker genes for determining renal toxicity
EP2891723B1 (en) Diagnosis and treatment of Alzheimer's disease
EP3093351B1 (en) Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
JP6448149B2 (ja) 肝線維症に関連する遺伝的多型、その検出方法および使用
EP3202914B2 (en) Method for treating a neurodegenerative disease
Okada et al. Genome‐wide analysis of genes related to kidney stone formation and elimination in the calcium oxalate nephrolithiasis model mouse: detection of stone‐preventive factors and involvement of macrophage activity
WO2007121922A2 (en) Biomarkers for chronic transplant dysfunction
US10704102B2 (en) Compositions and methods for diagnosing and monitoring hyperthyroidism in a feline
KR20090019848A (ko) 알쯔하이머 병의 진행에 대한 생체마커
US20160193364A1 (en) Compositions and methods for modulating mitochondrial pyruvate carrier activity
US20120134981A1 (en) Genes linking several complications of type-2 diabetes (t2d)
JP2004527229A (ja) 多型ｃｙｐ３ａ５発現の遺伝的決定基の同定
US20040248286A1 (en) Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof
Banno et al. Association of genetic polymorphisms of endothelin-converting enzyme-1 gene with hypertension in a Japanese population and rare missense mutation in preproendothelin-1 in Japanese hypertensives
US20110038944A1 (en) Compositions and methods for diagnosis and treatment of hepatobiliary disease and associated disorders
HK1084699A (en) Marker genes for determining renal toxicity
US20140023635A1 (en) Single nucleotide polymorphisms and genes associated with t2d-related complications
Fujii et al. Decreased IFT88 expression with primary cilia shortening causes mitochondrial
EP1514119A2 (en) DIAGNOSTIC POLYMORPHISM OF 11s-HYDROXYSTEROID DEHYDROGENASE USEFUL FOR IDENTIFYING RISK OF DEVELOPING ALZHEIMER S DISEA SE
CN101080501A (zh) 单核苷酸多态性(snp)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084699

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20051026

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1084699

Country of ref document: HK